Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2005-04-19
2005-04-19
Killos, Paul J. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C514S568000
Reexamination Certificate
active
06881860
ABSTRACT:
It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
REFERENCES:
patent: 4076841 (1978-02-01), Wagner et al.
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5770355 (1998-06-01), Brocia et al.
patent: 6121319 (2000-09-01), Somers
patent: 6147250 (2000-11-01), Somers
patent: 6323359 (2001-11-01), Jass
patent: 6448019 (2002-09-01), Mendelsohn et al.
patent: 212 310 (1987-03-01), None
patent: 254 272 (1988-01-01), None
patent: 292 660 (1988-11-01), None
patent: 348 203 (1989-12-01), None
patent: 418 648 (1991-03-01), None
patent: 2.130.975 (1972-11-01), None
patent: 2.133.024 (1972-11-01), None
patent: 2.134.810 (1972-12-01), None
patent: 2.140.769 (1973-01-01), None
patent: 2.168.137 (1973-08-01), None
patent: WO 9530415 (1995-11-01), None
patent: US 9608239 (1996-03-01), None
patent: WO 9608239 (1996-03-01), None
patent: WO 9726258 (1997-07-01), None
patent: WO 9830255 (1998-07-01), None
patent: WO 9851289 (1998-11-01), None
patent: WO 9851662 (1998-11-01), None
patent: 9851662 (1998-11-01), None
patent: WO 9924400 (1999-05-01), None
patent: WO 0026184 (2000-05-01), None
patent: WO 0028332 (2000-05-01), None
Rinninger et al.; Probucol Enhances Selective Uptake of HDL-Associated Cholesteryl Esters in Vitro by a Scavenger Receptor B-I-Dependent Mechanism; Arterioscler Thromb Vasc Biol.; Abstract XP 008001008; (1999); vol. 19, No. 5; pp. 1325-1332.
Combettes-Souverain et al.; SR-BI et métabolisme du cholestérol; Médecine Sciences; Abstract XP 008001010; (Nov. 1999); vol. 15, No. 11; pp. 1252-1258.
Meta et al.; Human Apolipoprotein A-I Gene Promoter Mutation Influences Plasma Low Density Lipoprotein Cholesterol Response to Dietary Fat Saturation; Atherosclerosis; Abstract XP-001061299; (1998); vol. 137 pp. 367-376.
Funke et al; Uptake of Apolipoprotein E-Containing High Density Lipoproteins by Hepatic Parenchymal Cells; Arteriosclerosis; Abstract XP 002001004; Sep./Oct., 1984); vol. 4, No. 5; pp. 452-461.
Miller et al; Apolipoprotein A-IZavalla(Leu159→Pro) HDL Cholesterol Deficiency in a Kindred Associated With Premature Coronary Artery Disease; Arterioscler Thromb Vasc Biol.; Abstract XP 008001006; (1998); vol. 18, No. 8; pp. 1242-1247.
Pfeuffer et al.; Probucol Increases the Selective Update of HDL Cholesterol Esters by Hep G2 Human Hepatoma Cells; Arteriosclerosis and Thrombosis; Abstract XP 008001007; (1992); vol. 12, No. 7; pp. 870-878.
Mao et al., “Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic Watanabe Rabbits,”Journal of Medicinal Chemistry, Jan. 1991, Vol. 34, No. 1, pp. 298-302.
Mao et al. “Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogue (MDL29,311) That Does Not Lower Serum Cholesterol,”Arteriosclerosis and Thrombosis, Sep./Oct. 1991, vol. 11, No. 5, pp. 1266-1275.
Ramasamy, Santhini et al., “Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, A Phenolic Antioxidant in Cultured Endothelial Cells,”Molecular Pharmacology, Apr. 5, 1999, vol. 56, pp. 116-123.
Chemical Abstract, Database Chemabs Online!, Chemical Abstracts Service, Columbus, Ohio, US, STN, Accession No. 127:75973, XP002115597, see abstract; RN 1706-68-9 & V.Z. Lankin et al.: DOKL. AKAD. NAUK, V. 351, No. 4, 1996, pp. 554-557.
Chemical Abstract, Database Chemabs Online!, Chemical Abstracts Service, Columbus, Ohio, US, STN, CAPLUS Accession No. 1970:445047, XP002124423, see abstract; RN 27428-10-0, 27428-13-3, 27428-14-4, 27428-15-5, 27428-16-6, 27428-17-7, 27428-18-8, 27428-19-9 & M. B. Neuworth et al.: J. Med. Chem., V. 13, No. 4, 1970, pp. 722-725.
Chemical Abstract, Database Chemabs Online!, Chemical Abstracts Service, Columbus, Ohio, US, STN, CAPLUS Accession No. 1986:28675, XP002124424, see abstract; RN 99661-86-6, 99661-87-7, 27466-44-0 & Chemical Abstracts, vol. 104, No. 5, Feb. 3, 1986, Columbus, Ohio, US; Abstract No. 28675, abstract & P. De Meglio et al.: Farmaco, Ed. Sci., vol. 40, No. 11, 1985, pp. 833-844.
Cominacini et al., “Antioxidants Inhibit the Expression of Intercellular Cell Adhesion molecule-1 and Vascular Cell Adhesion Molecule-1 Induced by Oxidized LDL on Human Umbilical Vein Endothelial Cells,”Free Radical Biology&Medicine, vol. 22, Nos. 1/2, pp. 117-127, 1997.
Feldman, Davis, et al., “The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881,”Atherosclerosis, Dec. 28, 1998, vol. 144, pp. 343-355.
Fruebis, Joachim, “A Comparison of the Antiatherogenic Effects of Probucol of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits,”The American Society for clinical Investigation, Inc., Jul. 1994, vol. 94, pp. 392-398.
Meng et al.; Novel Phenolic Antioxidants as Multifunctional Inhibitors of Inducible VCAM-1 Expression for Use in Antherosclerosis,Bioorganic&Medicinal Chemistry Letters; (2002); pp. 2545-2548.
Rinninger et al.; “Probucol Enhances Selective Uptake of HDL-Associated Cholesteryl Esters In Vitro by a Scavenger Receptor B-I-Dependent Mechanism,”Artherioscler Thromb Vasc Biol.; (1999); vol. 19; pp. 1325-1332.
Sawayama, et al.; “Effects of Probucol and Pravastatin on Common Carotid Atherosclerosis in Patients with Asymptomatic Hypercholesterolemia,”Journal of the American College of Cardiology; vol. 39; No. 4; (2002); pp. 610-616.
Luchoomun Jayraz
Meng Charles Q.
Saxena Uday
Sikorski James A.
Atherogenics, Inc.
Killos Paul J.
King & Spalding LLP
Knowles Sherry M.
LandOfFree
Compounds and methods to increase plasma HDL cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods to increase plasma HDL cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods to increase plasma HDL cholesterol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374758